Drug patent expiries aren’t just legal milestones—they’re commercial deadlines. And most companies treat them like a back-office event instead of a front-line growth strategy.
Here’s the agitation: when patent expiry dates are handled as static calenda…

Sell the line before the patent breaks. That’s the uncomfortable truth many pharma equipment suppliers learn the hard way: by the time a patent cliff hits, the deals are already decided—by competitors who moved earlier, engineered faster, and sold with…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

The “Smarter Monopoly” Question: Are Orphan Drug Exclusivities Helping Patients—or Just Pricing Power?
Big Pharma has always had a playbook: file patents early, extend them strategically, and defend market exclusivity like it’s a national resource. But…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Most business development teams in sterile manufacturing wait for the “cliff” moment—when a biologic’s loss of exclusivity (LOE) hits and …

Pharma’s “patent squeeze” isn’t just about patents—it’s about time.
For years, the public conversation around drug pricing has focused on one villain: the generic delay. But the more consequential story is often quieter—and more technical. It’s the way…

Patients aren’t asking “Can I switch?”—they’re asking “Will I be safe, covered, and able to afford it?”
If you’ve spent any time around drug pricing, pharmacy benefit design, or patent litigation, you know the public conversation often sounds like a te…

Evergreen the brand—or get ahead of it.
In pharma, “evergreening” isn’t a buzzword. It’s a playbook: extend exclusivity, delay generic entry, and protect revenue streams by layering new patents around an existing product. For innovators, it’s strategy….

GPT, Rosalind, and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes
In life sciences, the most expensive part of innovation isn’t always the science—it’s the time.
Time to search the literature. Time to interpret patents. Time to trans…

Patent cliffs don’t just erode revenue—they rewrite the rules of the market.
If you’re a pharma leader, payer strategist, or commercial operator, the “cliff” is rarely a single moment. It’s a cascade: formulary shifts, contracting renegotiations, uti…